Tag Archives: NASDAQ:BMRN

J.P. Morgan Sticks to Their Buy Rating for BioMarin (BMRN)

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on BioMarin (NASDAQ: BMRN) on August 2 and set a price target of $135. The company’s shares closed on Friday at $99.47. Kasimov commented: “BMRN reported an in-line 2Q after the

Analysts Conflicted on These Healthcare Names: BioMarin (NASDAQ: BMRN) and Quidel Corp (NASDAQ: QDEL)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin (NASDAQ:BMRN) and Quidel Corp (NASDAQ:QDEL). BioMarin (BMRN) Barclays analyst Gena Wang maintained a Hold rating on BioMarin on August 3 and set a price

J.P. Morgan Sticks to Its Buy Rating for BioMarin

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on BioMarin (NASDAQ: BMRN) on June 18. The company’s shares opened today at $95.94. According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 2.9% and a 38.8%

Wedbush Maintains a Buy Rating on BioMarin

Wedbush analyst Liana Moussatos maintained a Buy rating on BioMarin (NASDAQ: BMRN) today and set a price target of $115. The company’s shares closed on Friday at $92.49. According to TipRanks.com, Moussatos is a 4-star analyst with an average return

The CEO of BioMarin is Exercising Options

Yesterday, the CEO of BioMarin, Jean Jacques Bienaime, exercised options of BioMarin for $32.25K. Over the last month, Jean Jacques Bienaime has reported another 5 Buy trades on BMRN for a total of $1.22M. Based on BioMarin’s latest earnings report

Credit Suisse Maintains a Buy Rating on BioMarin

Credit Suisse analyst Alethia Young maintained a Buy rating on BioMarin (NASDAQ: BMRN) on March 27 and set a price target of $116. The company’s shares closed yesterday at $79.62, close to its 52-week low of $77.05. According to TipRanks.com,